D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Immunology D-index 53 Citations 11,518 152 World Ranking 2405 National Ranking 1165
Medicine D-index 70 Citations 21,040 292 World Ranking 15803 National Ranking 8150

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Gene

His primary areas of study are Immunology, Internal medicine, Melanoma, Immunotherapy and Talimogene laherparepvec. His Immunology study combines topics in areas such as Cancer and Vaccinia. His research integrates issues of Gastroenterology, Surgery and Oncology in his study of Internal medicine.

His work investigates the relationship between Melanoma and topics such as Ipilimumab that intersect with problems in Hydroxychloroquine, Autoimmune disease, Rheumatoid arthritis, Prednisone and CTLA-4. His biological study deals with issues like ELISPOT, which deal with fields such as ALVAC Vaccine, MART-1 Antigen, CD80 and Tumor microenvironment. The Talimogene laherparepvec study combines topics in areas such as Granulocyte macrophage colony-stimulating factor and Oncolytic virus.

His most cited work include:

  • Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma (1183 citations)
  • Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group (674 citations)
  • gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. (667 citations)

What are the main themes of his work throughout his whole career to date?

The scientist’s investigation covers issues in Immunotherapy, Internal medicine, Oncology, Immunology and Melanoma. His Immunotherapy research incorporates themes from Cancer research, Oncolytic virus and Virology. His study looks at the intersection of Internal medicine and topics like Surgery with Gastroenterology and Adverse effect.

His Overall survival study, which is part of a larger body of work in Oncology, is frequently linked to In patient, bridging the gap between disciplines. Immunology is closely attributed to Vaccinia in his research. As part of one scientific family, Howard L. Kaufman deals mainly with the area of Melanoma, narrowing it down to issues related to the Talimogene laherparepvec, and often Unresected and Stage iiib.

He most often published in these fields:

  • Immunotherapy (39.94%)
  • Internal medicine (39.07%)
  • Oncology (33.53%)

What were the highlights of his more recent work (between 2016-2021)?

  • Internal medicine (39.07%)
  • Oncology (33.53%)
  • Immunotherapy (39.94%)

In recent papers he was focusing on the following fields of study:

His primary areas of study are Internal medicine, Oncology, Immunotherapy, Cancer research and Melanoma. His Oncology research includes elements of Avelumab, Nivolumab and Surgery. He is conducting research in Cancer and Immunology as part of his Immunotherapy study.

His Cancer research focuses on Immune system and how it connects with Breast cancer. His Melanoma study combines topics from a wide range of disciplines, such as Gastroenterology, Talimogene laherparepvec, CD8 and Oncolytic virus. Howard L. Kaufman interconnects Oncolytic Virus Therapy and Ipilimumab in the investigation of issues within Talimogene laherparepvec.

Between 2016 and 2021, his most popular works were:

  • Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group (674 citations)
  • Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma (257 citations)
  • Combination immunotherapy: a road map (183 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Gene

His main research concerns Immunotherapy, Melanoma, Internal medicine, Cancer and Cancer research. His research integrates issues of Virus, Oncolytic virus, Tumor Cell Biology and Pandemic in his study of Immunotherapy. The Oncolytic virus study combines topics in areas such as Targeted therapy, Talimogene laherparepvec and Immunogenicity.

His Internal medicine research is multidisciplinary, relying on both Surgery and Oncology. In his study, Metastatic melanoma and Clinical study design is strongly linked to Immunology, which falls under the umbrella field of Oncology. His Cancer study integrates concerns from other disciplines, such as Adverse effect, Clinical trial and Immune system.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Robert H.I. Andtbacka;Howard L. Kaufman;Frances Collichio;Thomas Amatruda.
Journal of Clinical Oncology (2015)

1672 Citations

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

Douglas J. Schwartzentruber;David H. Lawson;Jon M. Richards;Robert M. Conry.
The New England Journal of Medicine (2011)

925 Citations

Oncolytic viruses: a new class of immunotherapy drugs

Howard L. Kaufman;Frederick J. Kohlhapp;Andrew Zloza.
Nature Reviews Drug Discovery (2015)

886 Citations

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

Howard L. Kaufman;Jeffery Russell;Omid Hamid;Shailender Bhatia.
Lancet Oncology (2016)

885 Citations

Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

I. Puzanov;A. Diab;K. Abdallah;C. O. Bingham.
Journal for ImmunoTherapy of Cancer (2017)

843 Citations

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

Neil N. Senzer;Howard L. Kaufman;Thomas Amatruda;Mike Nemunaitis.
Journal of Clinical Oncology (2009)

612 Citations

Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.

Howard L. Kaufman;Dae Won Kim;Gail DeRaffele;Josephine Mitcham.
Annals of Surgical Oncology (2010)

495 Citations

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

Douglas B. Johnson;Ryan J. Sullivan;Patrick A. Ott;Matteo S. Carlino.
JAMA Oncology (2016)

429 Citations

Characterization of CD4+CD25+ Regulatory T Cells in Patients Treated With High-Dose Interleukin-2 for Metastatic Melanoma or Renal Cell Carcinoma

Giovanni C. Cesana;Gail DeRaffele;Seth Cohen;Dorota Moroziewicz.
Journal of Clinical Oncology (2006)

407 Citations

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

Igor Puzanov;Mohammed M. Milhem;David Minor;Omid Hamid.
Journal of Clinical Oncology (2016)

404 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Howard L. Kaufman

Jeffrey Schlom

Jeffrey Schlom

National Institutes of Health

Publications: 113

James L. Gulley

James L. Gulley

National Institutes of Health

Publications: 88

John C. Bell

John C. Bell

University of Ottawa

Publications: 76

Francesco M. Marincola

Francesco M. Marincola

National Institutes of Health

Publications: 66

Lorenzo Galluzzi

Lorenzo Galluzzi

Cornell University

Publications: 61

Paolo A. Ascierto

Paolo A. Ascierto

National Institutes of Health

Publications: 59

James W. Hodge

James W. Hodge

National Institutes of Health

Publications: 55

Guido Kroemer

Guido Kroemer

Sorbonne University

Publications: 55

Dirk Schadendorf

Dirk Schadendorf

University of Duisburg-Essen

Publications: 51

Douglas B. Johnson

Douglas B. Johnson

Vanderbilt University Medical Center

Publications: 51

Jedd D. Wolchok

Jedd D. Wolchok

Memorial Sloan Kettering Cancer Center

Publications: 50

Akseli Hemminki

Akseli Hemminki

University of Helsinki

Publications: 49

Laurence Zitvogel

Laurence Zitvogel

Institut Gustave Roussy

Publications: 49

Kevin J. Harrington

Kevin J. Harrington

Royal Marsden NHS Foundation Trust

Publications: 46

Aurélien Marabelle

Aurélien Marabelle

Institut Gustave Roussy

Publications: 46

Michael A. Postow

Michael A. Postow

Memorial Sloan Kettering Cancer Center

Publications: 45

Trending Scientists

Remco Dijkman

Remco Dijkman

Eindhoven University of Technology

Thom Frühwirth

Thom Frühwirth

University of Ulm

Michael A. Clemens

Michael A. Clemens

Center for Global Development

Yannis Tsividis

Yannis Tsividis

Columbia University

Stephen M. Trimberger

Stephen M. Trimberger

Xilinx (United States)

Sergei Tretiak

Sergei Tretiak

Los Alamos National Laboratory

Uwe Manthe

Uwe Manthe

Bielefeld University

Sascha L. Hallett

Sascha L. Hallett

Oregon State University

J. M. Behnke

J. M. Behnke

University of Nottingham

Leo G. Nijtmans

Leo G. Nijtmans

Radboud University Nijmegen

Lluís Camarero

Lluís Camarero

Spanish National Research Council

Thomas R. Knutson

Thomas R. Knutson

Geophysical Fluid Dynamics Laboratory

Clayton T. Dickson

Clayton T. Dickson

University of Alberta

Jan R. Wessel

Jan R. Wessel

University of Iowa

Patti M. Valkenburg

Patti M. Valkenburg

University of Amsterdam

Martin Dennis

Martin Dennis

University of Edinburgh

Something went wrong. Please try again later.